Organization | Swedish Breast Cancer Group

Swedish Breast Cancer Group Report issue

Academic/Hospital Phase 3

Founded: Sweden (1970)

Organization Overview

First Clinical Trial

2001

NCT03888677

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2019

Timeline

NOW

Now

Alternative names

Swedish Breast Cancer Group

Active Ingredients

Drugs in Phase 3 Trials (8)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

cyclophosphamide (cytoxan) (4 trials)

docetaxel (taxotere) (2 trials)

epirubicin (ellence) (4 trials)

fluorouracil (efudex) (3 trials)

paclitaxel (taxol) (1 trial)

sargramostim (leukine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Inflammatory Breast Neoplasms (Phase 3)

Neoplasms (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 4
# of Trial APIs: 8